Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: azacitidine, decitabine | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 18 Parkinson's papers of 5,521 | 0.61 |
| pathways Reactome | 6 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 7676
Sealed predictions
- DNMT3A in dopamine neurons, braak+0.03 (p 0.947) → -0.42 (p 0.262)receipt 7684
Swarm cases
receipt 7684: DNMT3A in dopamine neurons, braak
- power
- full sample -0.24 (p 0.341, n 18), 95% CI -0.63 to +0.26. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.24 (p 0.337, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.30 (p 0.232, n 18). could be the mix.
- skeptic
- leave-one-out range -0.34 to -0.14, sign flips 0; without severely affected donors -0.24 (p 0.341, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DNMT3A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts